Fenofibrate causes regression of endometriotic implants: a rat model

Fertility and Sterility

Volumn 92, Issue 6, 2009, Pages 2100-2102

  Onalan, Gogsen ^a   Zeyneloglu, Hulusi B ^a   Bayraktar, Nilufer ^a  

^a BASKENT UNIVERSITY   (Turkey)

Author keywords

angiogenesis; Endometriosis; fenofibrate; rat; treatment

Indexed keywords

FENOFIBRATE; LEUPRORELIN; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG MEGADOSE; ENDOMETRIOSIS; FEMALE; LOW DRUG DOSE; NONHUMAN; PERITONEAL FLUID; PERITONEUM; PRIORITY JOURNAL; RAT;

ANIMALS; ANTILIPEMIC AGENTS; ASCITIC FLUID; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOMETRIOSIS; ENDOMETRIUM; FEMALE; NEOVASCULARIZATION, PATHOLOGIC; PROCETOFEN; RATS; RATS, WISTAR;

EID: 70749118968     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.fertnstert.2009.05.065     Document Type: Article

References (19)

1. Sampson J. Peritoneal endometriosis due to the menstrual dissemination of endothelial tissue into the peritoneal cavity. Am J Obstet Gynecol 14 (1927) 422-469
2. Taylor R.N., Lebovic D.I., and Mueller M.D. Angiogenic factors in endometriosis. Ann NY Acad Sci 955 (2002) 89-100 discussion 118, 396-406
3. Berger J., and Moller D.E. The mechanisms of action of PPARs. Annu Rev Med 53 (2002) 409-435
4. Delerive P., Fruchart J.C., and Staels B. Peroxisome proliferator-activated receptors in inflammation control. J Endocrinol 169 (2001) 453-459
5. Varet J., Vincent L., Mirshahi P., Pille J.V., Legrand E., Opolon P., et al. Fenofibrate inhibits angiogenesis in vitro and in vivo. Cell Mol Life Sci 60 (2003) 810-819
6. Panigrahy D., Kaipainen A., Huang S., Butterfield C.E., Barnés C.M., Fannon M., et al. PPARalpha agonist fenofibrate suppresses tumor growth through direct and indirect angiogenesis inhibition. Proc Natl Acad Sci U S A 105 (2008) 985-990
7. Yavuz E., Oktem M., Esinler I., AratToru S., and Zeyneloglu H.B. Genistein causes regression of endometriotic implants in the rat model. Fertil Steril 88 (2007) 1129-1134
8. Oktem M., Esinler I., Eroglu D., Haberal N., Bayraktar N., and Zeyneloglu H.B. High-dose atorvastatin causes regression of endometriotic implants: a rat model. Hum Reprod 22 (2007) 1474-1480
9. Soria A., Bocos C., and Herrera E. Opposite metabolic response to fenofibrate treatment in pregnant and virgin rats. J Lipid Res 43 (2002) 74-81
10. Colton H.M., Falls J.G., Ni H., Kwanyuen P., Creech D., McNeil E., et al. Visualization and quantitation of peroxisomes using fluorescent nanocrystals: treatment of rats and monkeys with fibrates and detection in the liver. Toxicol Sci 80 (2004) 183-192
11. Meissner M., Stein M., Urbich C., Reisinger K., Suske G., Staels B., et al. PPAR α activators inhibit vascular endothelial growth factor receptor-2 expression by repressing Sp1-dependent DNA binding and transactivation. Circ Res 94 (2004) 324-332
12. Dogan E., Saygili U., Posaci C., Tuna B., Caliskan S., Altunyurt S., et al. Regression of endometrial explants in rats treated with the cyclooxygenase-2 inhibitor rofecoxib. Fertil Steril 82 (2004) 1115-1120
13. Laschke M.W., and Menger M.D. In vitro and in vivo approaches to study angiogenesis in the pathophysiology and therapy of endometriosis. Hum Reprod Update 13 (2007) 331-342
14. Honda H., Barrueto F.F., Gogusev J., Im D.D., and Morin P.J. Serial analysis of gene expression reveals differential expression between endometriosis and normal endometrium. Possible roles for AXL and SHC1 in the pathogenesis of endometriosis. Reprod Biol Endocrinol 6 (2008) 59
15. Ferrero S., Ragni N., and Remorgida V. Antiangiogenic therapies in endometriosis. Br J Pharmacol 149 (2006) 133-135
16. Grau R., Punzon C., Fresno M., and Iniguez MA. Peroxisome-proliferator-activated receptor α agonists inhibit cyclo-oxygenase 2 and vascular endothelial growth factor transcriptional activation in human colorectal carcinoma cells via inhibition of activator protein-1. Biochem J 395 (2006) 81-88
17. Najib J. Fenofibrate in the treatment of dyslipidemia: a review of the data as they relate to the new suprabioavailable tablet formulation. Clin Ther 24 (2002) 2022-2050
18. Brown W.V. Focus on fenofibrate. Hosp Pract (OffEd) 23 Suppl 1 (1988) 31-40
19. Physicians' Desk Reference. Lofibra™ (Gate) fenofibrate capsules (micronized). Physicians' Desk Reference Electronic Library (2004), Thomson Micromedex, New York